Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Increases By 1,082.8%

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,530,000 shares, a growth of 1,082.8% from the October 15th total of 213,900 shares. Based on an average daily volume of 2,330,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 11.5% of the company’s shares are short sold.

Iterum Therapeutics Stock Performance

ITRM stock traded up $0.09 during mid-day trading on Tuesday, reaching $1.48. The company had a trading volume of 1,411,691 shares, compared to its average volume of 953,775. Iterum Therapeutics has a fifty-two week low of $0.71 and a fifty-two week high of $2.50. The company has a market capitalization of $33.61 million, a price-to-earnings ratio of -0.70 and a beta of 2.25. The firm has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $1.25.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.22. As a group, analysts predict that Iterum Therapeutics will post -1.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Iterum Therapeutics in a report on Tuesday, September 10th.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.